XML 42 R35.htm IDEA: XBRL DOCUMENT
v3.25.2

Collaboration Agreements, License Agreement and Revenues - Astellas Agreements - Additional Information (Detail) - USD ($) | 1 Months Ended | 3 Months Ended | 6 Months Ended |
--- | --- | --- | --- | ---
Apr. 30, 2006 | Jun. 30, 2005 | Jun. 30, 2025 | Jun. 30, 2024 | Jun. 30, 2025 | Jun. 30, 2024 | Dec. 31, 2024
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Total revenue |  |  | $ 1,348,000 | $ 998,000 | $ 4,088,000 | $ 26,363,000 |
Deferred Revenue |  |  | 27,311,000 |  | 27,311,000 |  | $ 27,290,000
Drug Product Revenue, Net [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Total revenue |  |  | 1,215,000 | 729,000 | 3,811,000 | 25,216,000 |
Japan [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Transaction price, variable consideration from estimated future co-development billing |  |  |  |  | 0 |  |
Europe [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Transaction price, variable consideration from estimated future co-development billing |  |  |  |  | $ 0 |  |
Astellas Agreement [Member] | Japan [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Upfront, non-contingent and time-based payments received |  | $ 172,600,000 |  |  |  |  |
Additional consideration based on net sales description |  |  |  |  | the low 20% range of the list price |  |
Aggregate consideration received excluding drug product revenue |  |  | 105,100,000 |  | $ 105,100,000 |  |
Transaction price, variable consideration from estimated future co-development billing |  |  | 0 | 0 | 0 | 0 |
Changes in revenue from changes to estimated variable consideration |  |  |  |  | 0 |  |
Astellas Agreement [Member] | Japan [Member] | License [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Cash Consideration Received Under Collaboration Agreement |  |  | 100,300,000 |  | 100,300,000 |  |
Astellas Agreement [Member] | Japan [Member] | Co-development, information sharing & committee services [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Cash Consideration Received Under Collaboration Agreement |  |  | 17,100,000 |  | $ 17,100,000 |  |
Astellas Agreement [Member] | Europe [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Upfront, non-contingent and time-based payments received | $ 745,000,000 |  |  |  |  |  |
Additional consideration based on net sales description |  |  |  |  | low 20% range |  |
Aggregate consideration received excluding drug product revenue |  |  | 685,000,000 |  | $ 685,000,000 |  |
Percentage of joint development costs committed to fund | 50.00% |  |  |  |  |  |
Changes in revenue from changes to estimated variable consideration |  |  | 0 |  |  |  |
Astellas Agreement [Member] | Europe [Member] | License [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Total revenue |  |  | 0 | $ 0 | 0 | $ 0 |
Cash Consideration Received Under Collaboration Agreement |  |  | 619,000,000 |  | 619,000,000 |  |
Astellas Agreement [Member] | Europe [Member] | Co-development, information sharing & committee services [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Cash Consideration Received Under Collaboration Agreement |  |  | $ 288,400,000 |  | $ 288,400,000 |  |

X
- Definition The amount of additional consideration based on net sales of product as defined under a collaboration agreement. + References No definition available. + Details
Name: | fgen_AdditionalConsiderationBasedOnNetSales
Namespace Prefix: | fgen_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The total cash consideration received under a collaboration agreement that has been allocated to the different significant units of accounting and includes the portion that has been deferred for revenue recognition. + References No definition available. + Details
Name: | fgen_CashConsiderationReceivedUnderCollaborationAgreement
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of aggregate consideration receivable under collaborative arrangement excluding drug product revenue. + References No definition available. + Details
Name: | fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents the percentage of costs that will be funded by the other party under a collaborative agreement for development costs. + References No definition available. + Details
Name: | fgen_PercentageOfFundingForCosts
Namespace Prefix: | fgen_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the amount of fixed and determinable non-contingent upfront payments included under the collaborative agreement as arrangement consideration. + References No definition available. + Details
Name: | fgen_ProceedsFromUpfrontNonContingentAndTimeBasedPayments
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Variable consideration payment received from estimated future co-development billing. + References No definition available. + Details
Name: | fgen_VariableConsiderationPaymentReceivedFromEstimatedFutureCoDevelopmentBilling
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 + Details
Name: | us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiabilityCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DrugProductRevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_JP
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=fgen_CoDevelopmentInformationSharingAndCommitteeServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |